Edgewise Therapeutics, Inc. (EWTX) Insider Trading
Over the last 3 months, EWTX insiders made 0 open-market buys and 21 sales, a net sale of -$9.8M (SEC Form 4). Over the last 6 months, 153 institutions increased and 144 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
21
Net (3m)
-$9.8M
Insider trades by month Buys Sells
Jan
Mar
Apr
May
Jul
Aug
Context3-month price +1.6%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Grant | 65,000 | $43.56 |
| Aug 17, 2026 | MOORE JOHN Rofficer: General Counsel | Grant | 65,000 | $43.56 |
| Aug 17, 2026 | Nofi Michaelofficer: Chief Financial Officer | Grant | 48,750 | $43.56 |
| Aug 17, 2026 | Derakhshan Behradofficer: Chief Business Officer | Grant | 100,000 | $43.56 |
| Aug 17, 2026 | Donovan Joanne M.officer: CMO | Grant | 65,000 | $43.56 |
| Aug 14, 2026 | KOCH KEVINdirector, officer: President and CEO | Grant | 100,000 | — |
| Aug 14, 2026 | KOCH KEVINdirector, officer: President and CEO | Grant | 200,000 | $43.56 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Sell | 2,839 | $43.78 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Sell | 2,779 | $43.71 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Sell | 104 | $44.43 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Sell | 800 | $44.52 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Sell | 2,919 | $43.41 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Grant | 32,500 | — |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Grant | 65,000 | — |
| Aug 14, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Option | 5,781 | — |
| Aug 14, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Option | 7,031 | — |
| Aug 14, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Sell | 3,238 | $43.68 |
| Aug 14, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Sell | 2,273 | $43.68 |
| Aug 14, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Sell | 390 | $44.46 |
| Aug 14, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Grant | 32,500 | — |
| Aug 14, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Grant | 65,000 | — |
| Aug 14, 2026 | MOORE JOHN Rofficer: General Counsel | Option | 5,781 | — |
| Aug 14, 2026 | MOORE JOHN Rofficer: General Counsel | Option | 6,718 | — |
| Aug 14, 2026 | MOORE JOHN Rofficer: General Counsel | Sell | 2,439 | $43.81 |
| Aug 14, 2026 | MOORE JOHN Rofficer: General Counsel | Sell | 59 | $44.41 |
| Aug 14, 2026 | MOORE JOHN Rofficer: General Counsel | Sell | 99 | $44.50 |
| Aug 14, 2026 | MOORE JOHN Rofficer: General Counsel | Sell | 2,419 | $43.80 |
| Aug 14, 2026 | MOORE JOHN Rofficer: General Counsel | Grant | 32,500 | — |
| Aug 14, 2026 | MOORE JOHN Rofficer: General Counsel | Grant | 65,000 | — |
| Aug 14, 2026 | Derakhshan Behradofficer: Chief Business Officer | Option | 5,781 | — |
Source: EWTX SEC Form 4 filings, latest Aug 17, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their EWTX positions over the last 6 months (SEC Form 13F).
Increased
153
New positions
86
Reduced
144
Sold out
26
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| ORBIMED ADVISORS LLC | Unchanged | 15.5M | May 15, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 15.5M | Aug 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 10.4M | May 15, 2026 |
| Paradigm Biocapital Advisors LP | Increased | 10.2M | Aug 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Reduced | 8.4M | Aug 14, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 7.4M | May 15, 2026 |
| BlackRock, Inc. | Increased | 6.6M | Aug 7, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 6.6M | May 15, 2026 |
| BLACKROCK, INC. | Reduced | 6.5M | May 13, 2026 |
| Jupiter Topco LLC | New Position | 6.1M | Aug 14, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 5.9M | May 18, 2026 |
| FMR LLC | Increased | 5.5M | Aug 13, 2026 |
| Novo Holdings A/S | Unchanged | 5.3M | Aug 14, 2026 |
| NOVO HOLDINGS A/S | Unchanged | 5.3M | May 15, 2026 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | Increased | 4.7M | Aug 14, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.